Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 1, 2020Cancer Management and ResearchOpen Access

Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

YWYanmei WuYZYu ZhangHPHao Pi

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Wu et al. (2020) studied this question.

synapsesocial.com/papers/6aa5c4347be4bb0a14f4bdc6https://doi.org/10.2147/cmar.s250632
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2− Breast Cancer2019 · 213 citations
  2. 2Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer2018 · 1,317 citations
  3. 3MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy2017 · 1,709 citations
  4. 4Thymidine Kinase 1 as a Tumor Biomarker: Technical Advances Offer New Potential to an Old Biomarker2018 · 93 citations